Def of cancer
Searched over 200M research papers
Summary
4 papers analyzed
These studies suggest that DEF6 and DEFA6 are associated with cancer progression and poor survival prognosis in various cancers, and they may serve as biomarkers and potential therapeutic targets, while deferasirox is a compound that can enhance the effects of certain chemotherapies in treating cancer.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Definition and Role of DEF6 in Cancer
DEF6 as a Cancer Biomarker
DEF6 Expression in Various Cancers
DEF6, a gene associated with the immune system, has been identified as a potential biomarker for cancer prognosis. Research indicates that DEF6 is commonly aberrantly expressed in various cancer types and is strongly correlated with survival prognosis. This gene is associated with multiple immune genes and is closely related to immune infiltration, suggesting its role in cancer pathways and oncogenic functions.
Prognostic Significance in Ovarian Carcinoma
In ovarian carcinoma, increased DEF6 expression correlates with poor patient survival. Studies show that DEF6, along with p16 and p53, plays a significant role in the regulation of cell cycle progression. High DEF6 expression is associated with the worst overall survival (OS) and disease-free survival (DFS) rates. This makes DEF6 an independent prognostic factor for ovarian carcinoma, indicating its potential as a target for therapeutic interventions.
DEF6 in Colorectal Cancer
Role in Tumorigenesis
DEF6 also plays a crucial role in colorectal cancer (CRC). It is highly expressed in CRC cell lines and patient-derived samples. Loss of DEF6 function impairs proliferation, migration, invasion, and colony-forming ability of CRC cells. Moreover, DEF6-deficient cancer cells exhibit significantly reduced growth rates in vivo. This highlights DEF6 as an essential oncogenic factor in CRC and a promising therapeutic target.
Therapeutic Implications
Combination Therapies
The potential of DEF6 as a therapeutic target extends to its role in combination therapies. For instance, the iron chelator deferasirox (Def) has shown synergistic effects when combined with chemotherapies like cisplatin and doxorubicin in non-small cell lung carcinoma (NSCLC). This combination leads to significant downregulation of genes related to resistance and metastasis, suggesting that targeting DEF6 could enhance the efficacy of existing cancer treatments.
Conclusion
DEF6 is a significant biomarker and therapeutic target in various cancers, including ovarian carcinoma and colorectal cancer. Its expression is closely linked to poor prognosis and survival rates, making it a critical focus for future cancer research and treatment strategies.
Sources and full results
Most relevant research papers on this topic
